Bio-Connect
Spike (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

Spike (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

Research Use Only
78349
BPS Bioscience
ApplicationsNeutralisation/Blocking
Product group Expression
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    BPS Bioscience
  • Product Name
    Spike (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
  • Delivery Days Customer
    7
  • Applications
    Neutralisation/Blocking
  • Certification
    Research Use Only
  • Scientific Description
    The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility. The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). Spike Mutations in B.1.1.529 Variant: A67V, delta69-70, T95I, G142D, delta143-145, delta211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
  • Storage Instruction
    -80°C
  • UNSPSC
    41106621